// App-Quantinova.ai

OP0223 : EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL

Researchers

Presenter

  • M. C. Genovese

Principal Investigators

  • A. Lertratanakul

  • J. Anderson

  • K. Papp

  • W. Tillett

  • F. Van den Bosch

  • S. Tsuji

  • E. Dokoupilova

  • M. Keiserman

  • X. Wang

  • S. Zhong

  • P. Zueger

  • A. Pangan

  • P. J. Mease

Medical Centers

  • Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, United States

  • K Papp Clinical Research, Probity Medical Research, Waterloo, Canada

  • Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

  • Hematology, Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium

  • Allegology, National Hospital Organization Osaka Minami Medical Center, Osaka, Japan

  • Medical Plus s.r.o., Uherske Hradiste, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic

  • Pontifical Catholic University of Rio Grande do Sul School of Medicine, Porto Alegre, Brazil

  • Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA

Locations

  • United States

  • Canada

  • United Kingdom

  • Belgium

  • Japan

  • Czech Republic

  • Brazil

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Psoriatic arthritis

  • Psoriasis

Biomarkers

  • Plasminogen Activator, Urokinase

  • Malondialdehyde

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved